A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.
We investigated in a rabbit model, the eye distribution of topically instilled benzalkonium_(BAK) chloride a commonly used preservative in eye drops using mass spectrometry imaging. Three groups of three New Zealand rabbits each were used: a control one without instillation, one receiving 0.01%BAK t...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0e48dab77fee420da2f8b75cb7178b4f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0e48dab77fee420da2f8b75cb7178b4f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0e48dab77fee420da2f8b75cb7178b4f2021-11-18T08:07:25ZA new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.1932-620310.1371/journal.pone.0050180https://doaj.org/article/0e48dab77fee420da2f8b75cb7178b4f2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23209668/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203We investigated in a rabbit model, the eye distribution of topically instilled benzalkonium_(BAK) chloride a commonly used preservative in eye drops using mass spectrometry imaging. Three groups of three New Zealand rabbits each were used: a control one without instillation, one receiving 0.01%BAK twice a day for 5 months and one with 0.2%BAK one drop a day for 1 month. After sacrifice, eyes were embedded and frozen in tragacanth gum. Serial cryosections were alternately deposited on glass slides for histological (hematoxylin-eosin staining) and immunohistological controls (CD45, RLA-DR and vimentin for inflammatory cell infiltration as well as vimentin for Müller glial cell activation) and ITO or stainless steel plates for MSI experiments using Matrix-assisted laser desorption ionization time-of-flight. The MSI results were confirmed by a round-robin study on several adjacent sections conducted in two different laboratories using different sample preparation methods, mass spectrometers and data analysis softwares. BAK was shown to penetrate healthy eyes even after a short duration and was not only detected on the ocular surface structures, but also in deeper tissues, especially in sensitive areas involved in glaucoma pathophysiology, such as the trabecular meshwork and the optic nerve areas, as confirmed by images with histological stainings. CD45-, RLA-DR- and vimentin-positive cells increased in treated eyes. Vimentin was found only in the inner layer of retina in normal eyes and increased in all retinal layers in treated eyes, confirming an activation response to a cell stress. This ocular toxicological study confirms the presence of BAK preservative in ocular surface structures as well as in deeper structures involved in glaucoma disease. The inflammatory cell infiltration and Müller glial cell activation confirmed the deleterious effect of BAK. Although these results were obtained in animals, they highlight the importance of the safety-first principle for the treatment of glaucoma patients.Françoise Brignole-BaudouinNicolas DesbenoitGregory HammHong LiangJean-Pierre BothAlain BrunelleIsabelle FournierVincent GuerineauRaphael LegouffeJonathan StauberDavid TouboulMaxence WisztorskiMichel SalzetOlivier LaprevoteChristophe BaudouinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 11, p e50180 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Françoise Brignole-Baudouin Nicolas Desbenoit Gregory Hamm Hong Liang Jean-Pierre Both Alain Brunelle Isabelle Fournier Vincent Guerineau Raphael Legouffe Jonathan Stauber David Touboul Maxence Wisztorski Michel Salzet Olivier Laprevote Christophe Baudouin A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| description |
We investigated in a rabbit model, the eye distribution of topically instilled benzalkonium_(BAK) chloride a commonly used preservative in eye drops using mass spectrometry imaging. Three groups of three New Zealand rabbits each were used: a control one without instillation, one receiving 0.01%BAK twice a day for 5 months and one with 0.2%BAK one drop a day for 1 month. After sacrifice, eyes were embedded and frozen in tragacanth gum. Serial cryosections were alternately deposited on glass slides for histological (hematoxylin-eosin staining) and immunohistological controls (CD45, RLA-DR and vimentin for inflammatory cell infiltration as well as vimentin for Müller glial cell activation) and ITO or stainless steel plates for MSI experiments using Matrix-assisted laser desorption ionization time-of-flight. The MSI results were confirmed by a round-robin study on several adjacent sections conducted in two different laboratories using different sample preparation methods, mass spectrometers and data analysis softwares. BAK was shown to penetrate healthy eyes even after a short duration and was not only detected on the ocular surface structures, but also in deeper tissues, especially in sensitive areas involved in glaucoma pathophysiology, such as the trabecular meshwork and the optic nerve areas, as confirmed by images with histological stainings. CD45-, RLA-DR- and vimentin-positive cells increased in treated eyes. Vimentin was found only in the inner layer of retina in normal eyes and increased in all retinal layers in treated eyes, confirming an activation response to a cell stress. This ocular toxicological study confirms the presence of BAK preservative in ocular surface structures as well as in deeper structures involved in glaucoma disease. The inflammatory cell infiltration and Müller glial cell activation confirmed the deleterious effect of BAK. Although these results were obtained in animals, they highlight the importance of the safety-first principle for the treatment of glaucoma patients. |
| format |
article |
| author |
Françoise Brignole-Baudouin Nicolas Desbenoit Gregory Hamm Hong Liang Jean-Pierre Both Alain Brunelle Isabelle Fournier Vincent Guerineau Raphael Legouffe Jonathan Stauber David Touboul Maxence Wisztorski Michel Salzet Olivier Laprevote Christophe Baudouin |
| author_facet |
Françoise Brignole-Baudouin Nicolas Desbenoit Gregory Hamm Hong Liang Jean-Pierre Both Alain Brunelle Isabelle Fournier Vincent Guerineau Raphael Legouffe Jonathan Stauber David Touboul Maxence Wisztorski Michel Salzet Olivier Laprevote Christophe Baudouin |
| author_sort |
Françoise Brignole-Baudouin |
| title |
A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| title_short |
A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| title_full |
A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| title_fullStr |
A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| title_full_unstemmed |
A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| title_sort |
new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/0e48dab77fee420da2f8b75cb7178b4f |
| work_keys_str_mv |
AT francoisebrignolebaudouin anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT nicolasdesbenoit anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT gregoryhamm anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT hongliang anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT jeanpierreboth anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT alainbrunelle anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT isabellefournier anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT vincentguerineau anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT raphaellegouffe anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT jonathanstauber anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT davidtouboul anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT maxencewisztorski anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT michelsalzet anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT olivierlaprevote anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT christophebaudouin anewsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT francoisebrignolebaudouin newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT nicolasdesbenoit newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT gregoryhamm newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT hongliang newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT jeanpierreboth newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT alainbrunelle newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT isabellefournier newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT vincentguerineau newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT raphaellegouffe newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT jonathanstauber newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT davidtouboul newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT maxencewisztorski newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT michelsalzet newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT olivierlaprevote newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits AT christophebaudouin newsafetyconcernforglaucomatreatmentdemonstratedbymassspectrometryimagingofbenzalkoniumchloridedistributionintheeyeanexperimentalstudyinrabbits |
| _version_ |
1718422151429619712 |